This report presents a framework to link science, policy and practice for a comprehensive assessment of climate mitigation and adaptation investments and their impact on human health.The framework proposes to use weather and climate data to forecast health impacts over time, as well as biophysical a...nd economic models to quantify the outcomes of investments in climate change adaptation and mitigation for relevant sectoral indicators and health co-benefits. It provides guidance on the economic valuation of health co-benefits of climate action, for inclusion in sector-specific cost–benefit analysis (CBA), including the spatial allocation of such costs and benefits.
The framework developed and presented in this study is comprehensive, and provides various entry points for different audiences, including decision-makers in the public and private sectors, researchers and scientists, working in the health sector as well as in other thematic areas and related sectors affected by climate action.
more
UNAIDS 2016, Reference
HIV care and support taking into account the 2016 WHO consolidated guidelines
The 2020 Report analyzes global health spending for 190 countries from 2000 to 2018 and provides insights as to the health spending trajectory from the MDG era to the SDG era prior to the crisis of 2020. The report shows that global spending on health continually rose between 2000 and 2018 and reach...ed US$ 8.3 trillion or 10% of global GDP. The data also show that out-of-pocket spending has remained high in low and lower-middle income countries, representing greater than 40% of total health spending in 2018. We also report and summarize the data on expenditures for PHC, as well as by disease and intervention, including for immunization. The report also analyzes the available data on budget allocation in response to the COVID-19 crisis. In addition, we combine World Bank/IMF projections of the macroeconomic and fiscal impact of the crisis with an analysis of the historical determinants of health spending patterns and UHC indicators, and based on this, we draw out the likely implications of 2020 for future health spending, highlighting key policy and monitoring concerns.
more
Guide à l’usage des établissements de santé.
Novembre 2015 Genève, Suisse.
Le présent guide présente plusieurs modèles de prise en charge différenciée, mis en oeuvre avec succès dans divers contextes et dans différents pays en Afrique subsaharienne. Il sera actualisé au fil des expé...riences rapportées concernant les démarches exposées ici ou d’autres démarches similaires.
more
Ces Directives sur la qualité de l’eau de boisson : petits approvisionnements en eau ont été élaborées pour aborder les besoins et les possibilités associés aux petits approvisionnements afin de favoriser l’amélioration progressive vers des services d’alimentation en eau de boisson sû...rs et durables pour tous. Ces directives se fondent sur la principale recommandation des Directives de qualité pour l’eau de boisson de l’Organisation mondiale de la santé ; elles visent à fournir des orientations concernant l’application de cette recommandation aux petits approvisionnements en eau en particulier. Ces directives visent à aider les gouvernements et les praticiens à améliorer la sécurité sanitaire de l’eau de boisson fournie par de petits approvisionnements.
more
10 years after the UN general assembly special session on drugs
In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems’ ability to prov...ide population-wide access to essential medicines.
Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products.
This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.
more
Strengthening HIV prevention among most-at-risk populations (MARPs) in the Syrian Arab Republic:
This field study to assess the pharmaceutical situation was undertaken in Ghana in May-June 2008 using a standardized methodology developed by the World Health Organization. The study assessed medicines availability and affordability, geographical accessibility, quality and r...ational use among other issues. The survey was conducted in six regions. In each region, 6 public health care facilities, 12 private pharmacies and 1 warehouse were surveyed.
more
Getting on track to end AIDS as a public health threat by 2030. This new Road Map charts a way forward for country-level actions to achieve an ambitious set of HIV prevention targets by 2025. Those targets emerged from the 2021 Political Declaration on HIV and AIDS, which the United Nations General ...Assembly adopted in June 2021 and they are underpinned by the Global AIDS Strategy (2021–2026). The Strategy sets out the principles, approaches, priority action area and programmatic targets for the global HIV response
more